Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Galapagos NV

Market Cap 1.64B 0 1.9B 1.51B 1.42B 2.66B 181B 2.7B 17.96B 6.97B 87.95B 7.13B 6.98B 305B P/E Ratio 2026 *
-10.8x
P/E Ratio 2027 * -9.97x
Enterprise Value -1.16B -0 -1.34B -1.07B -1B -1.88B -128B -1.9B -12.67B -4.92B -62.04B -5.03B -4.92B -215B EV / Sales 2026 *
-6.4x
EV / Sales 2027 * -4.93x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-12
Director of Finance/CFO 43 2025-07-06
Chief Tech/Sci/R&D Officer 61 2026-06-07
Director TitleAgeSince
Director/Board Member 64 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-12
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-0.22%-15.03%-12.88% 42.96B
+3.11%-1.17%+277.22%+502.47% 31.73B
+0.22%-2.90%+14.25%-12.16% 30.22B
+1.62%-5.52%+0.79%+22.42% 28.94B
+4.09%-1.98%+11.99%+17.37% 23.87B
-1.63%+1.89%+54.59%+124.83% 13.57B
-0.40%-1.48%+7.48%+7.12% 12.96B
+1.14%-0.36% - - 13.39B
-0.74%-2.47%+102.47%+80.26% 12.2B
Average +0.48%-0.71%+56.72%+91.18% 23.31B
Weighted average by Cap. +0.60%-1.08%+55.88%+95.96%

Financials

2026 *2027 *
Net sales 181M 0 209M 167M 156M 293M 19.93B 297M 1.98B 768M 9.69B 786M 769M 33.57B 177M 0 205M 164M 153M 287M 19.52B 291M 1.94B 753M 9.49B 770M 754M 32.89B
Net income -236M -0 -273M -217M -203M -381M -25.94B -387M -2.58B -1B -12.62B -1.02B -1B -43.7B -144M -0 -167M -133M -124M -233M -15.88B -237M -1.58B -612M -7.72B -626M -613M -26.74B
Net Debt -2.8B -0 -3.24B -2.58B -2.42B -4.53B -308B -4.6B -30.63B -11.89B -150B -12.17B -11.91B -520B -2.52B -0 -2.91B -2.32B -2.17B -4.07B -277B -4.13B -27.52B -10.68B -135B -10.93B -10.7B -467B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!